Acne Inversa Clinical Trial
Official title:
A PHASE 2A, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 16-WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF-06650833, PF-06700841, AND PF-06826647 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA
This is a study with 3 kinase inhibitors (PF 06650833, PF 06700841 and PF 06826647) in participants with moderate to severe HS. The study will have a maximum duration of approximately 26 weeks. This includes an up to 6-week Screening Period, a 16 week Dosing Period and a 4 week Follow up Period.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03275870 -
Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa
|
Phase 1/Phase 2 | |
| Completed |
NCT04019041 -
A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa
|
Phase 2 | |
| Terminated |
NCT03238469 -
Microwave Ablation in Mild Axillary Hidradenitis Suppurativa
|
N/A | |
| Completed |
NCT01352078 -
Wound Etiology and Healing Study
|
||
| Recruiting |
NCT04214483 -
A Pilot Study to Explore the Role of Gut Flora in Acne
|
||
| Not yet recruiting |
NCT06374212 -
Anifrolumab for Hidradenitis Suppurativa
|
Phase 2 | |
| Completed |
NCT03852472 -
Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)
|
Phase 2 | |
| Recruiting |
NCT03203122 -
Intense Pulsed Light Therapy for Hidrosadenitis Suppurativa
|
N/A | |
| Completed |
NCT04979520 -
Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa
|
Early Phase 1 | |
| Completed |
NCT04476043 -
To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa
|
Phase 2 |